
A bipartisan group is pushing Health and Human Services Secretary Xavier Becerra to allow imports of cheaper prescription drugs from Canada. Stat, meanwhile, reports on generic manufacturing plant closures’ impact on the Biden administration’s effort to boost drug supplies.
Sens. Amy Klobuchar (D-Minn.), Chuck Grassley (R-Iowa), Angus King (I-Maine) and Susan Collins (R-Maine) sent a letter to the secretary on Monday asking him to back policies permitting states and tribes to import certain prescription drugs from Canada.
In a letter, the senators argued that personal importation could deliver “a critical solution” to lowering medication costs, a goal of the Biden administration. The letter cited that almost 30 percent of adults say they don’t take their prescribed medications due to the cost.
“Americans should be able to obtain affordable medications, and expanding access to safe and affordable drugs in Canada can make a difference by providing direct relief to the millions of Americans who are struggling to afford the increasing cost of prescription drugs,” the letter reads.
“As the Administration considers options for lowering the cost of prescription drugs for patients, we urge your support for permanent solutions that will allow Americans to safely and personally import their medication,” the senators wrote.
The senators specifically called on Becerra to support the Safe and Affordable Drugs from Canada Act, reintroduced by Klobuchar and Grassley in February, that would permit drugs to be imported from the northern country.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
China Summons Delivery Giants Over Unfair Competition Concerns
May 13, 2025 by
CPI
Judge Orders Sanctions Against Missouri for Noncompliance in Price-Fixing Probe
May 13, 2025 by
CPI
Confusion Reigns In AI Policy In US and Europe
May 13, 2025 by
CPI
EU Clears ADNOC’s $16.3 Billion Acquisition of Covestro
May 13, 2025 by
CPI
Spanish Antitrust Chief Says BBVA-Sabadell Merger Won’t Stifle Competition
May 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece